BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, February 24, 2026
Home » Authors » Subhasree Nag

Articles by Subhasree Nag

Illustration of ovaries and uterus with endometriosis
Endocrine/Metabolic

Long-lasting effects by ‘recycled’ antibodies improve endometriosis lesions in primate study

March 1, 2023
By Subhasree Nag
A multi-institutional team of researchers has reported the development of an anti-IL-8 antibody against endometriosis using recycling antibody engineering technology. The study confirmed the role of the inflammatory cytokine IL-8 in the development of inflammation and fibrosis in endometriosis and showed that administration of IL-8 antibodies in primate models improved endometriosis pathology.
Read More
Endocrine/Metabolic

Post exercise, fibronectin drives insulin sensitization via liver autophagy

Feb. 23, 2023
By Subhasree Nag
Researchers led by Congcong He at Northwestern University have found that exercise caused contracting muscles to secrete a glycoprotein called fibronectin (FN1) that induced autophagy in the liver which, in turn, drove insulin sensitization. They reported their findings online in Cell Metabolism on Feb. 21, 2023. He is an assistant professor of cell and developmental biology at the Feinberg School of Medicine.
Read More
Expected omics results vs. actual omics results
Drug Design, Drug Delivery & Technologies

Incomplete databases can yield false positives in microbiome studies

Feb. 13, 2023
By Subhasree Nag
A study by researchers in Spain suggests that current metagenomic analyses of the microbiome can yield erroneous results, largely due to the incomplete databases that are used to identify microbial DNA sequences. A team led by Clemente Fernández Arias and Federica Bertocchini at the Centro de Investigaciones Biológicas Margarita Salas, Madrid, evaluated current microbiome analysis techniques on computer simulations of microbial communities in a report published on Feb. 8 in PLOS ONE.
Read More
Illustration of diabetic foot ulcer, cross section of wound
Endocrine/Metabolic

Reactivation of fetal protein can lead to improved diabetic wound healing

Feb. 3, 2023
By Subhasree Nag
Researchers at Indiana University School of Medicine are exploring avenues to heal wounds by identifying proteins that are active in fetuses, but largely inactive in adults and absent in diabetic adults. They have identified a protein called nonselenocysteine-containing phospholipid hydroperoxide glutathione peroxidase, or NPGPx, that fits the bill and could be the basis for therapies aimed at diabetic wound healing. NPGPx is a direct transcriptional target of miR-29. miR-29 is downregulated in fetal tissue, thus NPGPx is active in fetal tissue but becomes mostly inactive in the skin after birth.
Read More
Illustration of diabetic foot ulcer, cross section of wound
Endocrine/Metabolic

Reactivation of fetal protein can lead to improved diabetic wound healing

Feb. 2, 2023
By Subhasree Nag
Researchers at Indiana University School of Medicine are exploring avenues to heal wounds by identifying proteins that are active in fetuses, but largely inactive in adults and absent in diabetic adults. They have identified a protein called nonselenocysteine-containing phospholipid hydroperoxide glutathione peroxidase, or NPGPx, that fits the bill and could be the basis for therapies aimed at diabetic wound healing. NPGPx is a direct transcriptional target of miR-29. miR-29 is downregulated in fetal tissue, thus NPGPx is active in fetal tissue but becomes mostly inactive in the skin after birth.
Read More
Genetic/Congenital

Normal, mutant neurofibromin variants team up to drive severe neurofibromatosis

Jan. 26, 2023
By Subhasree Nag
In a study published in the online edition of Proceedings of the National Academy of Sciences on Jan. 23, 2023, a team of scientists from Frederick National Laboratory for Cancer Research and the University of California, San Francisco (UCSF) described how neurofibromin 1 (NF1) missense mutations act in a dominant negative manner through dimerization with wild-type neurofibromin.
Read More
DNA and cancer cells
Diagnostics

Cost-effective techniques for early cancer detection may be a diagnosis gamechanger in low-income countries

Jan. 18, 2023
By Subhasree Nag
Being able to detect cancers early can substantially improve survival, but most early detection tests for cancer rely on expensive and sophisticated molecular techniques that might be difficult to implement in resource strapped environments. Two new studies published last week attempt to overcome this problem.
Read More
Cancer

Mutations as well as tumor site predict treatment response in ovarian cancer

Dec. 22, 2022
By Subhasree Nag
Although ovarian cancers appear to be immunologically active, they do not respond well to immunotherapy in the clinic. In a study published on Dec. 14, 2022, in Nature, a multidisciplinary team at Memorial Sloan Kettering Cancer Center (MSK) led by Sohrab Shah and Dmitriy Zamarin has uncovered several mechanisms of immune evasion that can help explain why ovarian cancers have been resistant to immunotherapy to date.
Read More
Concept art of DNA, BRCA1/BRCA2 associated ovarian cancer.
Cancer

Alterations in DNA repair genes predict long-term survival in ovarian cancer

Dec. 13, 2022
By Subhasree Nag
Ovarian cancer is ordinarily associated with poor survival; patients diagnosed with high-grade serous ovarian carcinoma (HGSC) have an overall survival of about 40% at 5 years and 15% at 10 years. Despite having similar histologic features, HGSC patients often experience highly variable outcomes and the underlying determinants for long-term survival (LTS) are largely unknown. In a study published online in Nature Genetics, a multi-institutional group of researchers tried to determine the molecular differences that drive LTS in patients with HGSC.
Read More
Concept art of DNA, BRCA1/BRCA2 associated ovarian cancer.
Cancer

Alterations in DNA repair genes predict long-term survival in ovarian cancer

Dec. 12, 2022
By Subhasree Nag
Ovarian cancer is ordinarily associated with poor survival; patients diagnosed with high-grade serous ovarian carcinoma (HGSC) have an overall survival of about 40% at 5 years and 15% at 10 years. Despite having similar histologic features, HGSC patients often experience highly variable outcomes and the underlying determinants for long-term survival (LTS) are largely unknown. In a study published online in Nature Genetics, a multi-institutional group of researchers tried to determine the molecular differences that drive LTS in patients with HGSC.
Read More
Previous 1 2 3 4 5 6 7 8 9 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing